{"id":"entecavir-baraclude","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Lactic acidosis (rare but serious)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Entecavir is a nucleoside analog that selectively inhibits HBV polymerase (reverse transcriptase), preventing the conversion of pregenomic RNA to viral DNA. It also inhibits protein priming, a critical early step in HBV replication. This dual mechanism makes it highly potent against wild-type and lamivudine-resistant HBV strains.","oneSentence":"Entecavir inhibits hepatitis B virus reverse transcriptase and protein priming, blocking viral DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:30.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection in adults"},{"name":"Chronic hepatitis B infection in pediatric patients (2 years and older)"}]},"trialDetails":[{"nctId":"NCT07345624","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":80},{"nctId":"NCT07345611","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":60},{"nctId":"NCT04942886","phase":"NA","title":"Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation","status":"ENROLLING_BY_INVITATION","sponsor":"Seoul St. Mary's Hospital","startDate":"2021-08-21","conditions":"Hepatitis B Reactivation, Hematopoietic Stem Cell Transplantation, Antiviral Drug","enrollment":226},{"nctId":"NCT02496897","phase":"PHASE1","title":"Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2015-07","conditions":"Hepatitis B","enrollment":61},{"nctId":"NCT05484466","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB","status":"UNKNOWN","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2022-11-11","conditions":"Hepatitis B, Chronic","enrollment":90},{"nctId":"NCT02862548","phase":"PHASE2","title":"Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-09-16","conditions":"Chronic Hepatitis B","enrollment":51},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT03491553","phase":"PHASE2","title":"Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-04-06","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT04069858","phase":"PHASE4","title":"Maintaining Antiviral Efficacy After Switching to Generic Entecavir 1 mg for Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Korea University","startDate":"2016-12-01","conditions":"Chronic Hepatitis B","enrollment":40},{"nctId":"NCT03847246","phase":"NA","title":"Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2018-12-04","conditions":"Chronic Hepatitis b","enrollment":26},{"nctId":"NCT02881008","phase":"PHASE1, PHASE2","title":"Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hepatera Ltd.","startDate":"2012-11-14","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT01913431","phase":"PHASE4","title":"Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-09-12","conditions":"HBeAg-Positive Chronic Hepatitis B","enrollment":118},{"nctId":"NCT00614471","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-08","conditions":"Hepatitis B, Chronic","enrollment":219},{"nctId":"NCT01627223","phase":"PHASE4","title":"Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation","status":"TERMINATED","sponsor":"Taichung Veterans General Hospital","startDate":"2012-07","conditions":"Chronic Hepatitis B","enrollment":17},{"nctId":"NCT00940485","phase":"PHASE4","title":"A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04","conditions":"Hepatitis B, Chronic","enrollment":200},{"nctId":"NCT01341106","phase":"PHASE4","title":"Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2011-04","conditions":"Hepatitis B, Chronic, Liver Fibrosis","enrollment":7},{"nctId":"NCT02523547","phase":"PHASE4","title":"Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude","status":"UNKNOWN","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-01","conditions":"Chronic Hepatitis B","enrollment":134},{"nctId":"NCT01063036","phase":"PHASE3","title":"Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-05","conditions":"Chronic Hepatitis B","enrollment":144},{"nctId":"NCT01724723","phase":"PHASE4","title":"Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-12","conditions":"Hepatitis, Tuberculosis, hepatitisB","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BARACLUDE®"],"phase":"marketed","status":"active","brandName":"entecavir (BARACLUDE®)","genericName":"entecavir (BARACLUDE®)","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Entecavir inhibits hepatitis B virus reverse transcriptase and protein priming, blocking viral DNA replication. Used for Chronic hepatitis B infection in adults, Chronic hepatitis B infection in pediatric patients (2 years and older).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}